Skip to main content
. Author manuscript; available in PMC: 2014 Jul 8.
Published in final edited form as: Clin Ther. 2010 May;32(5):804–820. doi: 10.1016/j.clinthera.2010.05.003

Table IV.

Relationship of specific mutations to the efficacy of dasatinib and nilotinib in patients with chronic-phase chronic myeloid leukemia (CP CML).*

Rates of CCyR, n/N (%)
Mutation Dasatinib Nilotinib
Any mutation 158/369 (42.8) 18/77 (23.4)
P-loop mutations 61/141 (43.3) NR
  L248V NR 0/2
  G250E 19/51 (37.3) 1/4 (25.0)
  Y253F/H 12/23 (52.2) 0/8
  E255K/V 8/24 (33.3) 0/6
T315I 0/20 0/4
F317L 1/14 (7.1) NR†‡
F359C/V 14/27 (51.9) 0/10†

CCyR = complete cytogenetic response; NR = not reported.

*

Dasatinib data are based on 1093 patients with CP CML enrolled in clinical trials of dasatinib.73 Nilotinib data are based on 280 patients with CP CML enrolled in a Phase II clinical trial of nilotinib.82

†

Based on data from Hughes et al.90,100

‡

Considered a nilotinib-sensitive mutation (40.0% [18/45] of patients harboring nilotinib-sensitive mutations achieved a CCyR).100